国际中医中药杂志
國際中醫中藥雜誌
국제중의중약잡지
INTERNATIONAL JOURNAL OF TRIDITIONAL CHINESE MEDICINE
2013年
7期
607-609
,共3页
章晓鹰%徐平%张慧敏%李斌%余建秀
章曉鷹%徐平%張慧敏%李斌%餘建秀
장효응%서평%장혜민%리빈%여건수
抗炎一号%嗜碱性白血病细胞%脱颗粒%β-氨基己糖苷酶%IL-4%地塞米松
抗炎一號%嗜堿性白血病細胞%脫顆粒%β-氨基己糖苷酶%IL-4%地塞米鬆
항염일호%기감성백혈병세포%탈과립%β-안기기당감매%IL-4%지새미송
"Antiphlogistic No.1"%RBL-2H3%Degranultion%β-hexosaminidase%IL-4%Dexamethasone
目的 探讨抗炎一号对抗二硝基苯基化免疫球蛋白IgE(anti-dinitrophenol specific immunoglubinE,抗-DNP IgE)与二硝基苯基化牛白蛋白(dinitrophenol-bovine serum albumin,DNP-BSA)复合物刺激大鼠嗜碱性白血病细胞(RBL-2H3)脱颗粒与白细胞介素4(IL-4)释放的抑制作用,从而阐明其抗过敏机理.方法 用RBL-2H3细胞脱颗粒抑制率来评价抗炎一号细胞膜稳定作用,RBL-2H3细胞释放颗粒中的β-氨基己糖苷酶(β-hexosaminidase)与白细胞介素4(IL-4)分别用PNAG(ρ-硝基苯基-N-乙酰-β-D-氨基葡萄糖苷,ρ-nitrophenyl-N-acetyl-β-D-glucosaminide)底物反应比色法与ELISA方法检测.结果抗炎一号能抑制RBL-2H3细胞释放β-氨基己糖苷酶与IL-4,药物浓度为8 μg/ml时即具有42.47％的脱颗粒抑制作用(P＜0.01),浓度增至80μg/ml、800μg/ml、8000 μg/ml时,抑制率分别为52.40％、68.26％、72.15％,对IL-4释放抑制作用分别为13.87％、23.27％、31.95％、39.99％.抗炎一号β-氨基己糖苷酶释放最大抑制率为地塞米松最大抑制率的84.48％,抑制IL-4作用与地塞米松相当.结论 抗炎一号具有肥大细胞膜稳定作用,故可干预Ⅰ型变态反应.
目的 探討抗炎一號對抗二硝基苯基化免疫毬蛋白IgE(anti-dinitrophenol specific immunoglubinE,抗-DNP IgE)與二硝基苯基化牛白蛋白(dinitrophenol-bovine serum albumin,DNP-BSA)複閤物刺激大鼠嗜堿性白血病細胞(RBL-2H3)脫顆粒與白細胞介素4(IL-4)釋放的抑製作用,從而闡明其抗過敏機理.方法 用RBL-2H3細胞脫顆粒抑製率來評價抗炎一號細胞膜穩定作用,RBL-2H3細胞釋放顆粒中的β-氨基己糖苷酶(β-hexosaminidase)與白細胞介素4(IL-4)分彆用PNAG(ρ-硝基苯基-N-乙酰-β-D-氨基葡萄糖苷,ρ-nitrophenyl-N-acetyl-β-D-glucosaminide)底物反應比色法與ELISA方法檢測.結果抗炎一號能抑製RBL-2H3細胞釋放β-氨基己糖苷酶與IL-4,藥物濃度為8 μg/ml時即具有42.47％的脫顆粒抑製作用(P＜0.01),濃度增至80μg/ml、800μg/ml、8000 μg/ml時,抑製率分彆為52.40％、68.26％、72.15％,對IL-4釋放抑製作用分彆為13.87％、23.27％、31.95％、39.99％.抗炎一號β-氨基己糖苷酶釋放最大抑製率為地塞米鬆最大抑製率的84.48％,抑製IL-4作用與地塞米鬆相噹.結論 抗炎一號具有肥大細胞膜穩定作用,故可榦預Ⅰ型變態反應.
목적 탐토항염일호대항이초기분기화면역구단백IgE(anti-dinitrophenol specific immunoglubinE,항-DNP IgE)여이초기분기화우백단백(dinitrophenol-bovine serum albumin,DNP-BSA)복합물자격대서기감성백혈병세포(RBL-2H3)탈과립여백세포개소4(IL-4)석방적억제작용,종이천명기항과민궤리.방법 용RBL-2H3세포탈과립억제솔래평개항염일호세포막은정작용,RBL-2H3세포석방과립중적β-안기기당감매(β-hexosaminidase)여백세포개소4(IL-4)분별용PNAG(ρ-초기분기-N-을선-β-D-안기포도당감,ρ-nitrophenyl-N-acetyl-β-D-glucosaminide)저물반응비색법여ELISA방법검측.결과항염일호능억제RBL-2H3세포석방β-안기기당감매여IL-4,약물농도위8 μg/ml시즉구유42.47％적탈과립억제작용(P＜0.01),농도증지80μg/ml、800μg/ml、8000 μg/ml시,억제솔분별위52.40％、68.26％、72.15％,대IL-4석방억제작용분별위13.87％、23.27％、31.95％、39.99％.항염일호β-안기기당감매석방최대억제솔위지새미송최대억제솔적84.48％,억제IL-4작용여지새미송상당.결론 항염일호구유비대세포막은정작용,고가간예Ⅰ형변태반응.
Objective To investigate the direct effect of"Antiphlogistic No.1" on the degranultion of RBL-2H3 mast cells stimulated by anti-DNP IgE and DNP-BSA complex.Methods The effect of "Antiphlogistic No.1" on stabilization of RBL-2H3 cell membrane was assessed by degranultion inhibition rate.β-hexosaminidase and IL-4 released from RBL-2H3 cells were detected by PNAG colorimetric assay and ELISA.Results β-hexosaminidase and cytokine IL-4 production releases from RBL-2H3 cells was reduced after they had been treated with "Antiphlogistic No.1".The inhibition rate of β-hexosaminidase release was 42.47％ at the concentration of 8 μg/ml (P＜0.01) and dose dependently increased to 52.40％,68.26％ and 72.15％ respectively when drug concentration up to 80 μg/ml,800 μg/ml,8000 μg/ml,while inhibition rate of IL-4 generation were 13.87％,23.27％,31.95％,39.99％ (P＜0.01)."Antiphlogistic No.1" maximum inhibition rate of β-hexosaminidase release is 84.48％ of dexamethason maximum inhibition rate while "Antiphlogistic No.l" maximum inhibition rate of IL-4 is close to dexamethason maximum inhibition rate.Conclusion "Antiphlogistic No.1" could stabilize the cellular membrane of RBL-2H3 and provide protection against Ⅰ type allergic response.
